|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.72/-5.58
|
企业价值
2.03B
|
资产负债 |
每股账面净值
11.92
|
现金流量 |
现金流量率
--
|
损益表 |
收益
377.71M
|
每股收益
0.99
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/08 03:09 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201. |